Found: 238
Select item for more details and to access through your institution.
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Review: Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review.
- Published in:
- Medical Care Research & Review, 2011, v. 68, n. 3, p. 263, doi. 10.1177/1077558710394200
- By:
- Publication type:
- Article
A novel approach for establishing cardiovascular drug efficacy.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 12, p. 942, doi. 10.1038/nrd4090-c2
- By:
- Publication type:
- Article
Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
- Published in:
- Drugs in R&D, 2017, v. 17, n. 3, p. 441, doi. 10.1007/s40268-017-0201-0
- By:
- Publication type:
- Article
Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy.
- Published in:
- Nephrology Dialysis Transplantation, 2020, v. 35, p. ii38, doi. 10.1093/ndt/gfaa013
- By:
- Publication type:
- Article
Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials.
- Published in:
- Nephrology Dialysis Transplantation, 2019, v. 34, n. 10, p. 1699, doi. 10.1093/ndt/gfy159
- By:
- Publication type:
- Article
Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta.
- Published in:
- British Journal of Pharmacology, 1999, v. 126, n. 5, p. 1133, doi. 10.1038/sj.bjp.0702421
- By:
- Publication type:
- Article
Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.
- Published in:
- 1989
- By:
- Publication type:
- journal article
Unilateral renal parenchymal disease with contralateral renal artery stenosis of the fibrodysplasia type.
- Published in:
- 1989
- By:
- Publication type:
- journal article
Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2015, v. 53, n. 9, p. 1381, doi. 10.1515/cclm-2014-0894
- By:
- Publication type:
- Article
Low Levels of Urinary Albumin Excretion Are Associated with Cardiovascular Risk Factors in the General Population.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2000, v. 38, n. 11, p. 1107
- By:
- Publication type:
- Article
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.
- Published in:
- Kidney International, 2015, v. 87, n. 1, p. 20, doi. 10.1038/ki.2014.128
- By:
- Publication type:
- Article
The authors reply.
- Published in:
- 2014
- By:
- Publication type:
- commentary
The Authors Reply:.
- Published in:
- Kidney International, 2014, v. 86, n. 6, p. 1270, doi. 10.1038/ki.2014.263
- By:
- Publication type:
- Article
Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar.
- Published in:
- Kidney International, 2014, v. 86, n. 4, p. 819, doi. 10.1038/ki.2013.553
- By:
- Publication type:
- Article
Microalbuminuria: target for renoprotective therapy PRO.
- Published in:
- Kidney International, 2014, v. 86, n. 1, p. 40, doi. 10.1038/ki.2013.490
- By:
- Publication type:
- Article
LDL cholesterol in CKD-to treat or not to treat?
- Published in:
- Kidney International, 2013, v. 84, n. 3, p. 451, doi. 10.1038/ki.2013.181
- By:
- Publication type:
- Article
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers.
- Published in:
- Kidney International, 2012, v. 82, n. 3, p. 330, doi. 10.1038/ki.2012.74
- By:
- Publication type:
- Article
The Authors Reply:.
- Published in:
- 2012
- By:
- Publication type:
- Letter
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
- Published in:
- Kidney International, 2011, v. 80, n. 3, p. 282, doi. 10.1038/ki.2011.79
- By:
- Publication type:
- Article
Need for better diabetes treatment for improved renal outcome.
- Published in:
- Kidney International, 2011, v. 79, p. S28, doi. 10.1038/ki.2010.513
- By:
- Publication type:
- Article
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01964-8
- By:
- Publication type:
- Article
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA<sub>1c</sub>, disease duration and treatment intensity: results from the CANVAS Program.
- Published in:
- Diabetologia, 2021, v. 64, n. 11, p. 2402, doi. 10.1007/s00125-021-05524-1
- By:
- Publication type:
- Article
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
- Published in:
- Diabetologia, 2019, v. 62, n. 10, p. 1854, doi. 10.1007/s00125-019-4955-5
- By:
- Publication type:
- Article
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.
- Published in:
- Diabetologia, 2019, v. 62, n. 6, p. 926, doi. 10.1007/s00125-019-4839-8
- By:
- Publication type:
- Article
Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial.
- Published in:
- Diabetologia, 2018, v. 61, n. 3, p. 581, doi. 10.1007/s00125-017-4485-y
- By:
- Publication type:
- Article
Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.662642
- By:
- Publication type:
- Article
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3530, doi. 10.1111/dom.15685
- By:
- Publication type:
- Article
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 6, p. 2128, doi. 10.1111/dom.15518
- By:
- Publication type:
- Article
The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3724, doi. 10.1111/dom.15267
- By:
- Publication type:
- Article
The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2151, doi. 10.1111/dom.15091
- By:
- Publication type:
- Article
Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2419, doi. 10.1111/dom.15110
- By:
- Publication type:
- Article
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2218, doi. 10.1111/dom.15099
- By:
- Publication type:
- Article
Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1429, doi. 10.1111/dom.14731
- By:
- Publication type:
- Article
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2707, doi. 10.1111/dom.14525
- By:
- Publication type:
- Article
N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 12, p. 2899, doi. 10.1111/dom.13465
- By:
- Publication type:
- Article
Baseline characteristics and enrichment results from the SONAR trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 8, p. 1829, doi. 10.1111/dom.13315
- By:
- Publication type:
- Article
Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 8, p. 2019, doi. 10.1111/dom.13312
- By:
- Publication type:
- Article
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1369, doi. 10.1111/dom.13245
- By:
- Publication type:
- Article
Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1377, doi. 10.1111/dom.13226
- By:
- Publication type:
- Article
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 1, p. 224, doi. 10.1111/dom.13057
- By:
- Publication type:
- Article
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 10, p. 1363, doi. 10.1111/dom.12936
- By:
- Publication type:
- Article
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 7, p. 926, doi. 10.1111/dom.12924
- By:
- Publication type:
- Article
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 5, p. 749, doi. 10.1111/dom.12864
- By:
- Publication type:
- Article
Comparison of exposure response relationship of atrasentan between North American and Asian populations.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 4, p. 545, doi. 10.1111/dom.12851
- By:
- Publication type:
- Article
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal ( CANVAS-R): A randomized, placebo-controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 3, p. 387, doi. 10.1111/dom.12829
- By:
- Publication type:
- Article
The Role of Patients’ Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0139755
- By:
- Publication type:
- Article
A Panel of Novel Biomarkers Representing Different Disease Pathways Improves Prediction of Renal Function Decline in Type 2 Diabetes.
- Published in:
- PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0120995
- By:
- Publication type:
- Article
The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders.
- Published in:
- PLoS ONE, 2014, v. 9, n. 9, p. 1, doi. 10.1371/journal.pone.0108722
- By:
- Publication type:
- Article